



1P-736-T025

Monoclonal Antibody to CD88 / C5aR Phycoerythrin (PE) conjugated (25 tests)

Clone:	S5/1
Isotype:	Mouse IgG2a
Specificity:	The mouse monoclonal antibody S5/1 recognizes the CD88 protein, a 43 kDa receptor of C5a component of the complement cascade.
Regulatory Status:	RUO
Immunogen:	Recombinant N-terminal peptide (Asp15-Asp27) of human C5aR
Species Reactivity:	Human, Bovine, Rabbit, Ferret
Preparation:	The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
Storage Buffer:	The reagent is provided in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide.
Storage / Stability:	Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Usage:	The reagent is designed for Flow Cytometry analysis of human blood cells using 10 µl reagent / 100 µl of whole blood or 10 ⁶ cells in a suspension. The content of a vial (0.25 ml) is sufficient for 25 tests.
Expiration:	See vial label
Lot Number:	See vial label
Background:	CD88 / C5aR is a G protein-coupled seven membrane-spanning protein serving as a receptor for C5a component of the complement cascade, and is expressed mainly by monocytes, macrophages, neutrophils, eosinophils, and mast cells, but also e.g. by hepatocytes, glial cells, vascular endothelial cells, or cardiomyocytes. The binding of C5a to CD88 is associated with inflammatory response, including superoxide anion production, chemotaxis, and increased production of acute phase proteins. Expression of CD88 on synovial mast cells and their C5a-mediated degranulation plays a role in pathogenesis of rheumatoid arthritis.
References:	*Kiener HP, Baghestanian M, Dominkus M, Walchshofer S, Ghannadan M, Willheim M, Sillaber C, Graninger WB, Smolen JS, Valent P: Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. <i>Arthritis Rheum.</i> 1998 Feb;41(2):233-45. *Conway Morris A, Kefala K, Wilkinson TS, Dhaliwal K, Farrell L, Walsh T, Mackenzie SJ, Reid H, Davidson DJ, Haslett C, Rossi AG, Sallenave JM, Simpson AJ: C5a mediates peripheral blood neutrophil dysfunction in critically ill patients. <i>Am J Respir Crit Care Med.</i> 2009 Jul 1;180(1):19-28. *Cain SA, Monk PN: The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74). <i>J Biol Chem.</i> 2002 Mar 1;277(9):7165-9. *Camous L, Roumenina L, Bigot S, Brachemi S, Frémeaux-Bacchi V, Lesavre P, Halbwachs-Mecarelli L: Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. <i>Blood.</i> 2011 Jan 27;117(4):1340-9.

For laboratory research only, not for drug, diagnostic or other use.



Antibodies

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

For laboratory research only, not for drug, diagnostic or other use.

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic
Tel: +420 261 090 666 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz